Cellectar Biosciences, Inc. (CLRB)

NASDAQ: CLRB · IEX Real-Time Price · USD

2.520

-0.110 (-4.18%)

At close: Jul 19, 2024, 4:00 PM

2.670

+0.150 (5.95%)

Pre-market: Jul 22, 2024, 7:38 AM EDT

Cellectar Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2004
Selling, General & Admin	13.32	10.75	9.59	6.54	5.15	5.18	Upgrade
Research & Development	28.94	28.21	19.22	17.59	10.14	9	Upgrade
Operating Expenses	42.26	38.96	28.81	24.13	15.29	14.18	Upgrade
Operating Income	-42.26	-38.96	-28.81	-24.13	-15.29	-14.18	Upgrade
Other Expense / Income	8.79	-0.92	-0.15	-0.01	-0.2	-0.09	Upgrade
Pretax Income	-51.04	-38.04	-28.66	-24.12	-15.09	-14.09	Upgrade
Income Tax	-0.06	-0.06	-0.06	0	0	0	Upgrade
Net Income	-50.98	-37.98	-28.6	-24.12	-15.09	-14.09	Upgrade
Shares Outstanding (Basic)	29	12	7	6	2	1	Upgrade
Shares Outstanding (Diluted)	29	12	7	6	2	1	Upgrade
Shares Change	160.60%	73.22%	27.09%	180.20%	158.14%	159.12%	Upgrade
EPS (Basic)	-3.08	-3.11	-4.05	-4.35	-7.60	-18.40	Upgrade
EPS (Diluted)	-3.08	-3.11	-4.05	-4.35	-7.60	-18.40	Upgrade
Free Cash Flow	-39.44	-33.24	-25.45	-22.71	-14	-11.72	Upgrade
Free Cash Flow Per Share	-1.34	-2.72	-3.61	-4.09	-7.06	-15.27	Upgrade
EBITDA	-50.75	-37.79	-28.42	-23.89	-14.89	-13.9	Upgrade
Depreciation & Amortization	0.3	0.25	0.24	0.23	0.21	0.19	Upgrade
EBIT	-51.04	-38.04	-28.66	-24.12	-15.09	-14.09	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).